4D Molecular Therapeutics legal chief sells 1,635 shares

The option award vests in 1/48 increments monthly and becomes fully vested and exercisable on its fourth anniversary, while Scott Bizily remains a service provider.

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. (FDMT) Chief Legal Officer Scott Bizily exercised options for 1,635 shares of common stock on October 16, 2026, at an exercise price of $4.14 per share, then sold 1,635 shares at $12.84 per share. The transactions were made under a Rule 10b5-1 trading plan adopted January 13, 2026. His reported post-transaction option position covered 56,431 shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,635 shares ($14K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Bizily Scott

Role Chief Legal Officer

Sold 1,635 shs ($21K)

Approx. gross sale proceeds $21K

Approx. exercise cost $7K

Approx. pre-tax spread $14K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F2	1,635	$0.00	$0.00
Exercise	Common Stock F1	1,635	$4.14	$7K
Sale	Common Stock F1	1,635	$12.84	$21K

Holdings After Transaction: Stock Option (Right to Buy) — 56,431 contracts (Direct); Common Stock — 8,617 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.
2. F2. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Key Figures

Options exercised: 1,635 shares Exercise price: $4.14 per share Shares sold: 1,635 shares +2 more

5 metrics

Options exercised 1,635 shares October 16, 2026

Exercise price $4.14 per share Options exercised October 16, 2026

Shares sold 1,635 shares October 16, 2026

Sale price $12.84 per share Sale on October 16, 2026

Post-transaction option position 56,431 shares Reported following the October 16, 2026 transaction

Key Terms

10b5-1 trading plan, Vesting Commencement Date, fully vested and exercisable

3 terms

10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan"

A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.

Vesting Commencement Date technical

"the "Vesting Commencement Date""

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

fully vested and exercisable technical

"fully vested and exercisable on the fourth anniversary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many FDMT shares did Scott Bizily exercise and sell, and at what prices?

Scott Bizily exercised options for 1,635 shares of FDMT common stock at an exercise price of $4.14 per share and sold 1,635 shares at $12.84 per share on October 16, 2026. The transactions were made under a Rule 10b5-1 trading plan adopted January 13, 2026.

How does Scott Bizily's FDMT stock option vest?

The option award vests as to 1/48 of the underlying shares on each monthly anniversary of March 6, 2025, while Scott Bizily remains a service provider. It becomes fully vested and exercisable on the fourth anniversary of that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/20/2026 - 04:56 PM EDT Accepted by SEC EDGAR 10/20/2026 - 04:56 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bizily Scott

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS, INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/16/2026		M(1)		1,635	A	$4.14	10,252	D
Common Stock	10/16/2026		S(1)		1,635	D	$12.84	8,617	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.14	10/16/2026		M(1)			1,635	(2)	03/05/2035	Common Stock	1,635	$0	56,431	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.

2. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

	/s/ Scott Bizily	10/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)